| Date Filed | Type | Description |
| 10/13/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 09/27/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/20/2023 |
8-K
| Quarterly results |
| 07/11/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 06/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...|
Docs:
|
"1,447,628 SHARES OF COMMON STOCK, 3,908 SHARES OF SERIES F CONVERTIBLE PREFERRED STOCK",
"KIORA PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS",
"KIORA PHARMACEUTICALS, INC. and VSTOCK TRANSFER, LLC, as Warrant Agent",
"Kiora Pharmaceuticals Announces Closing of" |
|
| 06/02/2023 |
424B1
| Form 424B1 - Prospectus [Rule 424(b)(1)]: |
| 06/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/15/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 05/12/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/09/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 04/27/2023 |
8-K
| Quarterly results |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 4.8% stake in KIORA PHARMACEUTICALS, INC. |
| 02/14/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/13/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/08/2023 |
SC 13G/A
| INTRACOASTAL CAPITAL, LLC reports a 9% stake in Kiora Pharmaceuticals, Inc. |
| 02/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/03/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 01/09/2023 |
8-K
| Investor presentation |
| 01/03/2023 |
8-K
| Other Events Interactive Data |
| 12/29/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/28/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 11/21/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 11/21/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...|
Docs:
|
"COMMON STOCK PURCHASE WARRANT kiora pharmaceuticals, inc. Warrant Shares: _______ Issue Date: November __, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May __, 2023 and on or prior to 5:00 p.m. on the 18-month anniversary of the Initial Exercise Date but not thereafter, to subscribe for and purchase from Kiora Pharmaceuticals, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . In addition to the terms defined elsewhere in this...",
"Annex A – Representations and Warranties",
"Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants" |
|
|